Patterson, Thomas F.

Remdesivir for the Treatment of Covid-19 — Final Report

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 7,267

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 4,917

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 3,304

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 2,926

Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)

Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 1,570

Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database

Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 1,456

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 1,001

Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 791

Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment

Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 707

Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients

Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 470

Invasive Non- Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006

Park, B. J., Pappas, P. G., Wannemuehler, K. A., Alexander, B. D., Anaissie, E. J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., et al. (2011) · Emerging Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 321

Factors associated with mortality in transplant patients with invasive aspergillosis

Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityImmunodeficiency and Autoimmune Disorders

Cited by 303

In Vitro Activity of Caspofungin against Candida albicans Biofilms

Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityBacterial biofilms and quorum sensing

Cited by 288

Calcineurin Controls Growth, Morphology, and Pathogenicity in Aspergillus fumigatus

Steinbach, W. J., Cramer, R. A., Perfect, B. Z., Asfaw, Y. G., Sauer, T. C., Najvar, L. K., Kirkpatrick, W. R., Patterson, T. F., Benjamin, D. K., Heitman, J., et al. (2006) · Eukaryotic Cell

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 264

Distinct Patterns of Gene Expression Associated with Development of Fluconazole Resistance in Serial Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis

Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 210

Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing

White, P. L., Wingard, J. R., Bretagne, S., Löffler, J., Patterson, T. F., Slavin, M. A., Barnes, R. A., Pappas, P. G., & Donnelly, J. P. (2015) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 193

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 192

The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)

Andes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 182

Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method

Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 133

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.

Vazquez, J., Reboli, A. C., Pappas, P. G., Patterson, T. F., Reinhardt, J., Chin-Hong, P., Tobin, E., Kett, D. H., Biswas, P., & Swanson, R. (2014) · BMC Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 101

Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure

Lewis, J. S., Wiederhold, N. P., Wickes, B. L., Patterson, T. F., & Jorgensen, J. H. (2013) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 101

Early treatment of candidemia in adults: a review

Ostrosky-Zeichner, L., Kullberg, B. J., Bow, E. J., Hadley, S., León, C., Nucci, M., Patterson, T. F., & Perfect, J. R. (2011) · Medical Mycology

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 97

Antifungal Combinations against Candida albicans Biofilms In Vitro

Bachmann, S. P., Ramage, G., VandeWalle, K., Patterson, T. F., Wickes, B. L., & López-Ribot, J. L. (2003) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 89

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 88